<DOC>
	<DOCNO>NCT02105792</DOCNO>
	<brief_summary>This study examine extreme responder second- third-line Type 2 diabetes therapy use prospective approach , patient slow fast diabetes progression use retrospective approach .</brief_summary>
	<brief_title>PROMASTER - PROspective Cohort MRC ABPI STratification Extreme Response Mechanism Diabetes</brief_title>
	<detailed_description>PILOT Phase ( March 2013 - Dec 2014 ) Participants recruit initially 4 centre . Patients due start second- third-line Type 2 diabetes treatment , patient progress insulin either particularly quickly particularly slowly , recruit primary care , secondary care , community setting . Fasting blood urine sample collect , together standard biomeasures information medical history prescribe history . Participants Responders Arm contact telephone approximately 3 month start new second/third-line agent review current medication blood glucose level . If 3 month HbA1c collect part routine clinical care , research team arrange . Participants ask return blood urine test approximately 6 month new treatment start . This visit bring forward participant advise change treatment , enable sample collect advance propose treatment change . All study documentation sample material distribute site Coordinating Centre . Sites expect process freeze sample send Chief Investigator 's Central Laboratory analyse genetic factor , glycaemic marker marker related drug response . POST-PILOT Phase ( Jan 2015 - Oct 2017 ) Subject feasibility , interim analysis continuation fund Medical Research Council ( MRC ) , study continue another 3 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Demographics : Age 1890 inclusive Ethnicity : Reflective local demographic Medical History : Clinical diagnosis Type 2 diabetes Mental Capacity : Capacity Consent Age less 18 year old great 90 year old Incapacity consent Type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetes therapy response</keyword>
	<keyword>Diabetes progression</keyword>
</DOC>